Table 1. Demographic and Clinical Characteristics of Participants.

			Grade of Disease
	All Patients		III		IV
Variable	No.	%	No.	%	No.	%
Total patients	237	100	73	31	164	69
Age, years
Mean	50		44		52
SD	12		11		11
< 45	79	33	38	52	41	25
≥ 45	158	67	35	48	123	75
Male sex	161	68	50	68	111	68
Karnofsky performance status
70	11	5	4	5	7	4
80	74	31	20	27	54	33
90	121	51	41	56	80	49
100	31	13	8	11	23	14
Status of disease at diagnosis
Active	42	18	12	16	30	18
Stable	195	82	61	84	134	82
No. of prior treatments
1	22	9	4	5	18	11
2	74	31	25	34	49	30
3	76	32	19	26	57	35
≥ 4	65	27	25	34	40	24
No. of prior progressions
0	17	7	7	10	10	6
1	132	56	37	51	95	58
2	58	24	12	16	46	28
≥ 3	30	13	17	23	13	8
Receiving salvage therapy at testing
No	31	13	9	12	22	13
Yes	206	87	64	88	142	87
Receiving bevacizumab
No	120	51	38	52	82	50
Yes	117	49	35	48	82	50
Receiving dexamethasone
No	167	70	55	75	112	68
Yes	68	29	16	22	52	32
Unknown	2	1	2	3	0	0
Receiving anti-epileptic medication
No	57	24	16	22	41	25
Yes	180	76	57	78	123	75
FACT-G: Physical well-being (range 0-28)
Median	23		22		24
Minimum – Maximum	4 - 28		5 - 28		4 - 28
FACT-G: Functional well-being (range 0-28)
Median	20		19		20
Minimum – Maximum	4 - 28		5 - 28		4 - 28
FACT-G: Emotional well-being (range 0-24)
Median	19		19		19
Minimum – Maximum	4 - 24		4 - 24		9 - 24
FACT-G: Social well-being (range 0-28)
Median	24		23		24
Minimum – Maximum	6 - 28		6 - 28		9 - 28
FACT-G: Total score (range 0-108)
Median	84		83		85
Minimum – Maximum	34 - 108		34 - 105		37 - 108
FACT-Br: Brain Cancer Subscale (range 0-76)
Median	52		53		52
Minimum – Maximum	12 - 76		12 - 76		24 - 76
FACT-Br: Total score (range 0-184)
Median	136		131		138
Minimum – Maximum	46 - 182		46 - 176		72 - 182
FACT-Br: Trial Outcome Index (range 0-132)
Median	94		94		95
Minimum – Maximum	25 - 130		25 - 128		43 - 130
FACIT-Fatigue Subscale (range 0-52)
Median	36		34		36
Minimum – Maximum	10 - 46		10 - 46		11 - 45